{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.50","upperLimit":"79.75","value":"57.9"},{"groupId":"OG001","lowerLimit":"8.52","upperLimit":"75.51","value":"37.5"},{"groupId":"OG002","lowerLimit":"9.90","upperLimit":"81.59","value":"42.9"},{"groupId":"OG003","lowerLimit":"38.44","upperLimit":"81.89","value":"61.9"},{"groupId":"OG004","lowerLimit":"24.49","upperLimit":"91.48","value":"62.5"},{"groupId":"OG005","lowerLimit":"9.43","upperLimit":"99.16","value":"66.7"},{"groupId":"OG006","lowerLimit":"42.52","upperLimit":"82.03","value":"64.0"},{"groupId":"OG007","lowerLimit":"46.50","upperLimit":"85.05","value":"68.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"25"}],"units":"Participants"}],"description":"The DCR was defined as the proportion of participants with a confirmed response of sCR, CR, VGPR, PR, MR, or stable disease (SD) during the study per investigator assessment as defined by IMWG Uniform Response Criteria. PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \\<200 mg/24 hours. CR: negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and \\<5% plasma cells in bone marrow. sCR: CR+normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis, or ≥90% reduction in serum M-protein plus urine M-protein \\<100 mg/24 hours. MR: ≥25% but ≤49% reduction of serum M-protein and reduction in 24-hour urine M-protein by 50% to 89%. SD: no known evidence of progressive or new bone lesions if radiographic studies were performed. Percentages were rounded off to the nearest decimal.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received modakafusp alfa 0.001 up to 0.75 mg/kg, infusion, IV, Q1W on Days 1, 8, 15 and 22 of each 28-day treatment cycle up to 2 cycles, followed by Q2W on Days 1 and 15 of each 28-day treatment cycle up to 4 cycles, followed by Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"OG000","title":"Part 1 (Dose Escalation) Schedule A"},{"description":"Participants received modakafusp alfa 0.20 up to 0.30 mg/kg, infusion, IV, Q2W on Days 1 and 15 of each 28-day treatment cycle until treatment discontinuation.","id":"OG001","title":"Part 1 (Dose Escalation) Schedule B"},{"description":"Participants received modakafusp alfa 0.40 up to 0.75 mg/kg, infusion, IV, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"OG002","title":"Part 1 (Dose Escalation) Schedule C"},{"description":"Participants received modakafusp alfa 1.5 up to 6.0 mg/kg, infusion, IV, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"OG003","title":"Part 1 (Dose Escalation) Schedule D"},{"description":"Participants received modakafusp alfa 0.400 mg/kg infusion, IV, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"OG004","title":"Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa"},{"description":"Participants received modakafusp alfa 0.400 mg/kg infusion, IV, and dexamethasone 40 mg, orally, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"OG005","title":"Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa + Dexamethasone"},{"description":"Participants received modakafusp alfa 1.500 mg/kg infusion, IV, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"OG006","title":"Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa"},{"description":"Participants received modakafusp alfa 1.500 mg/kg infusion, IV, and dexamethasone 40 mg, orally, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"OG007","title":"Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"The SAS included all enrolled participants who received at least 1 dose, even if incomplete, of TAK-573 and with measurable disease at baseline. Overall number of participants analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Up to 54.3 months in Part 1; Up to 34.7 months in Part 2","title":"Parts 1 and 2: Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}